Back
 WJA  Vol.1 No.4 , December 2011
Role of HIV-1 Viral Load in Initiating Antiretroviral Therapy
Abstract: Purpose: For commencement of Antiretroviral Therapy (ART), CD4 count and/or WHO clinical staging is used as the guide in India. In western countries along with clinical and immunological criteria, HIV-1 viral load is also used to start the patient on treatment. The present study was conducted to determine the role of viral load in taking decision on ART commencement in HIV-1 infected treatment naïve individuals. Method: A cross sectional study was carried out at the Integrated Counseling and Testing Centre (ICTC) in the Department of Microbiology at a Tertiary care teaching hospital after Institutional Ethics Committee approval. After obtaining written informed consent, HIV-1 infected patients who were clinically asymptomatic, ART naïve, having CD4 count <250 cells/mm3 and age more than or equal to 15 yrs were enrolled in this study. Blood sample was collected and viral load was estimated by COBAS® TaqMan® HIV-1 Test. Result: During the study period of one year, 8966 HIV-1 infected patients were referred for CD4 count estimation. Of these 1624 patients had CD4 count <250 cells/mm3 and 405 patients were treatment naïve. Of these 96 (23.70%) patients were clinically asymptomatic and were enrolled. Of those enrolled, ten (10.41%) had viral load less than 5000 copies/ml. Conclusion: Decision to start patient on ART can be made judiciously when viral load is used along with CD4 count estimation.
Cite this paper: nullN. Ingole, S. Kukreja and P. Mehta, "Role of HIV-1 Viral Load in Initiating Antiretroviral Therapy," World Journal of AIDS, Vol. 1 No. 4, 2011, pp. 149-154. doi: 10.4236/wja.2011.14022.
References

[1]   A. Calmy, N. Ford, B. Hirschel, S. J. Reynolds, L. Lynen, E. Goemaere, F. G. de la Vega, L. Perrin and W. Rodriguez, “HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary?” Clinical Infectious Diseases, Vol. 44, No. 1, 2007, pp. 128-134. doi:10.1086/510073

[2]   WHO, “Antiretroviral Therapy for HIV Infection in Adults and Adolescents, Recommendations for a Public Health Approach 2010 Revision,” 2010. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf

[3]   NACO, “Antiretroviral Therapy Guidelines for HIV In-fected Adults and Adolescents Including Post Exposure Prophylaxis,” Ministry of Health and Family Welfare, 2007. http://www.nacoonline.org/upload/Policies%20&%20Guidelnes/1.%20Antiretroviral%20Therapy%20Guidelines% 20for%20HIVInfected%20Adults%20and%20Adolescents%20Including%20Post-exposure.pdf

[4]   Y. Pirzada, S. Khuder and H. Donabedian, “Predicting AIDS-Related Events Using CD4 Percentage or CD4 Absolute Counts,” AIDS Research and Therapy, Vol. 3, 2006, p. 20. doi:10.1186/1742-6405-3-20

[5]   R. Kannangai, A. J. Kandathil, D. L. Ebenezer, G. Nithyanandam, P. Samuel, O. C. Abraham, T. D. Sudarsanam, S. A. Pulimood and G. Sridharan, “Evidence for Lower CD4+ T Cell and Higher Viral Load in Asymptomatic HIV-1 Infected Individuals of India: Implications for Therapy Initiation,” Indian Journal of Medical Microbiology, Vol. 26, No. 3, 2008, pp. 217-221. doi:10.4103/0255-0857.42031

[6]   M. Irwin, “Low CD4+ T Lymphocyte Counts: A Variety of Causes and Their Implications to a Multifactorial Model of AIDS,” Virusmyth Homepage, 2001. “http://www.virusmyth.com/aids/hiv/milowcd4.htm

[7]   K. Ray, S. M. Gupta, M. Bala, S. Muralidhar and J. Kumar, “CD4/CD8 Lymphocyte Counts in Healthy, HIV-Positive Individuals & AIDS Patients,” Indian Journal of Medical Research, Vol. 124, 2006, pp. 319-330.

[8]   V. S. Attili, S. Sundar, V. P. Singh and M. Rai, “Validity of Existing CD4+ Classification in North Indians, in Predicting Immune Status,” Journal of Infection, Vol. 51, No.1, 2005, pp. 41-46. doi:10.1016/j.jinf.2004.08.022

[9]   A. D. Kimmel, M. C. Weinstein, X. Anglaret, S. J. Goldie, E. Losina, Y. Yazdanpanah, E. Messou, K. L. Cotich, R. P. Walensky and K. A. Freedberg, “Monitoring of Antiretroviral Therapy in Resource-limited Settings: Discussion,” Journal of Acquired Immunodeficiency Syndrome, Vol. 54, No. 3, 2010, pp. 258-268. doi:10.1097/QAI.0b013e3181d0db97

[10]   B. Boughton, “WHO-Mandated CD4 Monitoring for HIV Shows Poor Sensitivity, Specificity,” 17th Conference on Retroviruses and Opportunistic Infections (CROI), Abstract 111, San Francisco, 18 February 2010. http://www.medscape.com/viewarticle/717302

[11]   E. Mylonakis, M. Paliou and J. D. Rich, “Plasma Viral Load Testing in the Management of HIV Infection,” American Family Physician, Vol. 63, No. 3, 2001, pp. 483-490.

[12]   M. B. Cauldbeck, C. O’Connor, M. B O’Connor, J. A. Saunders, B. Rao, V. G. Mallesh, N. Kotehalappa, P. Kumar, G. Mamtha, C. McGoldrick, R. B. S. Laing and K. S. Satish, “Adherence to Anti-Retroviral Therapy among HIV Patients in Bangalore, India,” AIDS Research and Therapy, Vol. 6, 2009, p. 7. doi:10.1186/1742-6405-6-7

[13]   R. Murri, A. Ammassari, A. De Luca, A. Cingolani, P. Marconi, A. W. Wu and A. Antinori, “Self-Reported Non- adherence with Antiretroviral Drugs Predicts Persistent Condition,” HIV Clinical Trials, Vol. 2, No.4, 2001, pp. 323-329. doi:10.1310/KDM0-RU5W-NVTW-N9MC

[14]   F. Forna, C. A. Liechty, P. Solberg, F. Asiimwe, W. Were, J. Mermin, P. Behumbiize, T. Tong, J. T. Brooks and P. J. Weidle, “Clinical Toxicity of Highly Active Antiretroviral Therapy in a Home-Based AIDS Care Program in Rural Uganda,” Journal of Acquired Immunodeficiency Syndrome, Vol. 44, No.4, 2007, pp. 456-462. doi:10.1097/QAI.0b013e318033ffa1

[15]   R. Nuesch, P. Srasuebkul, J. Ananworanich, K. Ruxrungtham, P. Phanuphak and C. Duncombe, “Monitoring the Toxicity of Antiretroviral Therapy in Resource Limited Settings: A Prospective Clinical Trial Cohort in Thailand,” Journal of Antimicrobial Chemotherapy, Vol. 58, No. 3, 2006, pp. 637-644. doi:10.1093/jac/dkl313

[16]   C. Adje, R. Cheingsong-Popov, T. Roels, G. Djomand, et al., “High Prevalence of Genotypic Antiretroviral (ART) Drug-Resistant HIV-1 Strains among HIV-1-Infected Patients Receiving ART in Abidjan, Ivory Coast,” Conference on Retroviruses and Opportunistic Infections, San Francisco, 30 January - 2 February 2000. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102243620.html

[17]   P. Scott, E. Arnold, B. Evans, A. Pozniak, G. Moyle, M. Shahmenesh, D. White, J. Shirley, P. Cane and D. Pillay, “Surveillance of HIV Antiretroviral Drug Resistance in Treated Individuals in England:1998-2000,” Journal of Antimicrobial Chemotherapy, Vol. 54, No. 3, 2003, pp. 469-473.

[18]   J. W. Mellors, A. Munoz, J. V. Giorgi, J. B. Margolick, C. J. Tassoni, P. Gupta, L. A. Kingsley, J. A. Todd, A. J. S. R. Detels, J. P. Phair and C. R. Rinaldo Jr., “Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection,” Annals of Internal Medicine, Vol. 126, 1997, pp. 946-954.

[19]   S. Napravnik, C. Poole, J. C. Thomas and J. J. Eron Jr., “Gender Difference in HIV RNA Levels: A Meta-Analysis of Published Studies,” Journal of Acquired Immunodeficiency Syndrome, Vol. 31, No. 1, 2002, pp. 11-19. doi:10.1097/01.QAI.0000026906.47530.AB

[20]   S. B. Shade, C. Rappoport, D. LeSueur and M. C. Eberly, “Gender Differences in Viral Load: Results from Six Clinical Trials,” International Conference on AIDS, Durban, 9-14 July 2000. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102238735.html

 
 
Top